COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03342937
Recruitment Status : Active, not recruiting
First Posted : November 17, 2017
Last Update Posted : December 24, 2020
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Duke University

Brief Summary:

This study will be conducted in two stages: 1) safety validation and 2) dose expansion

  1. Safety Validation Cohort: The first portion of the study will preliminarily establish the tolerability of the combination of pembrolizumab, oxaliplatin and capecitabine. Five (5) subjects will be enrolled and their safety data after 21 days of treatment will be reviewed before additional subjects are enrolled. Subjects on this portion of the study will only be enrolled at the Duke Cancer Institute.
  2. Dose Expansion Cohort: The second portion of the study (ie. phase II) will enroll 30 subjects. In the dose expansion cohort, the first cycle will be modified to allow one week of pembrolizumab monotherapy before starting capecitabine and oxaliplatin (XELOX) chemotherapy, which will allow analysis of biomarkers related to pembrolizumab. Subjects on this portion of the study will be enrolled at the Duke Cancer institute and select external collaborating institutions.

The primary objective of this trial is to describe the progression free survival (PFS) associated with the combination of pembrolizumab, oxaliplatin and capecitabine (pembrolizumab +XELOX) in all patients with previously untreated metastatic esophagogastric adenocarcinoma.

Condition or disease Intervention/treatment Phase
Gastric Cancer Esophagus Cancer Drug: Oxaliplatin+Capecitabine+Pembrolizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients With Gastro-esophageal Cancer.
Actual Study Start Date : January 11, 2018
Estimated Primary Completion Date : January 22, 2022
Estimated Study Completion Date : January 22, 2024

Arm Intervention/treatment
Experimental: Oxaliplatin+Capecitabine+Pembrolizumab Drug: Oxaliplatin+Capecitabine+Pembrolizumab

For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1.

This study has 2 parts:

  1. Safety validation part: all Cycles are 21 days in length.
  2. Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days.

Primary Outcome Measures :
  1. Progression-free survival (PFS) as measured by documented progression or death from any cause. [ Time Frame: Up to 2 years ]

Secondary Outcome Measures :
  1. Over all survival as measured by follow up [ Time Frame: Up to 2 years ]
  2. Number of adverse events [ Time Frame: From the first dose of study drug through 30 days after the last dose of study drug ]
    All grade 2-5 Adverse events must be recorded on the case report form (CRF)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically and/or cytologically documented and radiographically measurable (by RECIST 1.1) adenocarcinoma of the esophagus or stomach (HER2-positive or negative) that is metastatic/recurrent and not amenable to potentially curative treatment
  • No prior chemotherapy for metastatic/recurrent disease. Prior adjuvant or neo-adjuvant treatment with a fluoropyrimidine or fluoropyrimidine based regimen is allowed only if it is completed at least 6 months prior to the start of study drug, whether given alone or with radiation therapy. Patients who have received prior neo-adjuvant therapy (chemotherapy and/or radiation therapy) which did not contain 5-FU or capecitabine and have been diagnosed with metastatic disease (with no previous treatment in the metastatic setting) are eligible. No 6-months window is required for these patients. In the setting of metastatic disease requiring local palliation, only radiosensitizing doses of 5-FU or capecitabine monotherapy are permitted.
  • Prior radiation therapy is permitted, provided is completed at least 28 days prior to the start of study drug.
  • Age ≥ 18 years with ability to understand and willingness to provide informed consent.
  • ECOG performance status of 0 or 1.
  • Adequate organ and marrow function as defined below by the following:

    1. Absolute neutrophil count (ANC) ≥ 1500 µl
    2. Platelets ≥ 100,000/µl
    3. Hemoglobin (Hgb) ≥ 9 g/dL
    4. Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
    5. AST/ALT ≤ 2 x ULN without liver metastasis; ≤ 5 x ULN with liver metastasis
    6. Creatinine clearance ≥ 50 cc/min

Exclusion Criteria:

  • Prior therapy with an anti-PD-1, anti PD-L1, anti-PD-L2, anti-CD137 antibody, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) agents.
  • Chemotherapy, targeted small molecule therapy, radiotherapy, experimental agents, prior therapy with anti-tumor vaccines or other immune-stimulatory antitumor agents, or biological cancer therapy (including monoclonal antibodies) within 14 days prior to the start of study drug, or not recovered (≤ grade 1 or baseline) from adverse events due to a previously administered agent.
  • Known CNS metastases and/or carcinomatous meningitis. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 30 days prior to the start of study drug.
  • Documented history of clinically significant autoimmune disease (other than well-controlled hypothyroidism) or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo, type I diabetes mellitus, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  • Receiving systemic steroid therapy or any form of immunosuppressive therapy within 1 week prior to the start of study drug.
  • Received a live vaccine within 4 weeks prior to the start of the study drug.
  • Has known history of, or any evidence of active, non-infectious pneumonitis.
  • Known history of HIV seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment. Patients receiving prophylactic antibiotics (e.g., for prevention of urinary tract infection or chronic obstructive pulmonary disease) are eligible.
  • Pregnant or breastfeeding
  • Not willing to use an effective method of birth control
  • Concurrent severe and/or uncontrolled medical conditions, which may compromise participation in the study, including impaired heart function or clinically significant heart disease.
  • Current use of medication specified by the protocol as prohibited for administration in combination with the study drug. This includes patients with a condition requiring systemic treatment with either corticosteroids (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to the start of study drug. Inhaled or topical steroids and adrenal replacement doses > 10mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • Recent or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment within 2 weeks prior to the start of study drug.
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the start of study drug (56 days for hepatectomy, open thoracotomy, major neurosurgery) or anticipation of need for major surgical procedure during the course of the study (except fot rhe planned metastatectomy).
  • Serious, non-healing wound, ulcer, or bone fracture.
  • History of myocardial infarction, NYHA lass III or IV congestive heart failure, arrhythmia requiring therapy, unstable angina, cardia or other vascular stenting, angioplasty, or surgery within 6 months prior to the start of study drug.
  • History of other carcinomas within the last five years, except cured non-melanoma skin cancer, curatively treated in-situ cervical cancer, or localized prostate cancer with a current PSA of < 1.0mg/dL on 2 successive evaluations, at least 3 months apart, with the most recent evaluation no more than 4 weeks prior to the start of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03342937

Layout table for location information
United States, North Carolina
Johnston Health Services Corporation
Clayton, North Carolina, United States, 27520
Duke Cancer Center, Duke University
Durham, North Carolina, United States, 27710
Maria Parham Healthcare Association
Henderson, North Carolina, United States, 27536
Scotland Health Care System
Laurinburg, North Carolina, United States, 28352
Southeastern Regional Medical Center
Lumberton, North Carolina, United States, 28358
Johnston Health Services Corporation
Smithfield, North Carolina, United States, 27577
United States, South Carolina
Lexington Medical Center
West Columbia, South Carolina, United States, 29169
Sponsors and Collaborators
Duke University
Merck Sharp & Dohme Corp.
Layout table for investigator information
Principal Investigator: Hope Uronis, MD Duke University
Layout table for additonal information
Responsible Party: Duke University Identifier: NCT03342937    
Other Study ID Numbers: Pro00080566
First Posted: November 17, 2017    Key Record Dates
Last Update Posted: December 24, 2020
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Duke University:
gastric cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Head and Neck Neoplasms
Esophageal Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Immunological